News

At 12 months, patients with congestive heart failure and/or left atrial enlargement had an atrial fibrillation detection rate of 23.4% vs 5.0% for patients with neither attribute.

A meta-analysis suggests that 100mg/w rituximab for 3 consecutive weeks may be the appropriate dosage for patients of NMOSD, demonstrated by a low risk of adverse events.

The division chief of stroke and vascular neurology at Duke Health discussed advantages and capabilities, as well as limitations and barriers of transcranial direct current stimulation to treat poststroke symptoms. [WATCH TIME: 4 minutes]

Six months after hospital discharge, COVD-19 headache was more frequently observed in those infected with the Delta variant vs Wuhan or Alpha variants.

The executive vice principal of advocacy and healthcare access at the National MS Society spoke on how the Inflation Reduction Act of 2022 will impact patients with MS and what the clinical community should be aware of. [WATCH TIME: 5 minutes]

The codirector of the ALS Center at Washington University School of Medicine in St. Louis provided perspective on the phase 3 VALOR findings of tofersen, an antisense agent currently under review to treat SOD1-mutated ALS.

The ongoing phase 1/2a MONARCH study continued to display a well-tolerated safety profile for single and multiple doses of STK-001 in children and adolescents with Dravet Syndrome.

The newly announced prospective, randomized, placebo- and sham-controlled study, will include 150 patients, ages 18 to 55 years, with documented patent foramen ovale and a history of more than 1 migraine headache day per week.

The chief of neurology and codirector of the neuroscience Center at the Children's Hospital of Philadelphia, spoke about the wellbeing of pediatric patients with MS in reference to her presentation at ECTRIMS 2022. [WATCH TIME: 4 minutes]

Evidence of therapeutic benefit for zavegepant was observed on multiple secondary end points, including return to normal function at 30 min postdose, sustained pain relief, and sustained pain freedom.

The assistant professor of medicine at University of Toronto, and neurologist at St. Michael's Hospital spoke about the process of changing or beginning treatment with a variety of disease-modifying therapies in multiple sclerosis. [WATCH TIME: 4 minutes]

Zilucoplan, a complement C5 inhibitor, demonstrated a safe and tolerable profile, while meeting its primary and secondary end points in the phase 3 RAISE trial—the basis for its new drug application.

The GRADUATE studies, which spanned across 32 countries, showed minimal relative reduction in clinical decline for those on gantenerumab relative to placebo over a 116-week treatment cycle.

Here's some of what is coming soon to NeurologyLive® this week.

The 26-patient trial includes 10 individuals with early-manifest Huntington disease on low-dose AMT-130 and 16 in the high-dose cohort, which will continue enrollment after a DSMB found no further safety concerns.

The founder and executive director of the Sumaira Foundation discussed her experience living with NMOSD and the global organization she created to help patients with the same condition. [WATCH TIME: 6 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromuscular disorders.

Jennifer Roggenbuck, MS, LGC, an associate professor of neurology and internal medicine at The Ohio State University Wexner Medical Center, discussed her presentation on evidence-based consensus guidelines for genetic testing and counseling from the 2022 NEALS Consortium.

Neurology News Network for the week ending November 12, 2022. [WATCH TIME: 4 minutes]

James Wymer, MD, FAAN, discussed his presentation at the 2022 Annual NEALS meeting on improving speech and swallowing using Neudexta for patients with ALS.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 11, 2022.

The codirector of the ALS Center at Washington University School of Medicine provided perspective on the lessons learned from the trials of tofersen, as it aims to become the first FDA-approved therapy specific to SOD1 ALS. [WATCH TIME: 4 minutes]

A phase 1/2a clinical trial resulted in showing that a single dosing of AstroRx was safe and tolerable, at either a low or high dose, for patients with ALS.

IPX203, an oral formulation of carbidopa/levodopa, the standard treatment for Parkinson disease, demonstrated statistically significant results in improving ON time relative to immediate release CD/LD.

The chief of neurology and codirector of the neuroscience Center at the Children's Hospital of Philadelphia spoke about her presentation at ECTRIMS 2022 on the treatment of pediatric MS. [WATCH TIME: 5 minutes]

The Child Neurology Foundation is using community outreach and a new social services network to help children with neurological conditions feel included in contemporary society.

The codirector of the ALS Center at Washington University School of Medicine in St. Louis provided background on how tofersen would be used alongside other ALS medications if approved. [WATCH TIME: 3 minutes]

More than half of the cohort achieved no evidence of disease activity and few patients showed disability progression after 48 weeks of treatment with ocrelizumab.